Clinical Trial Update: A Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Participants With Treatment Resistant Depression [Phase 2]

View source ↗

Summary

Phase 2 study in Japanese participants evaluated fixed-dose intranasal esketamine for treatment-resistant depression; the trial completed and results were poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder
• Treatment-resistant Depression

Drugs mentioned

• SPRAVATO (ESKETAMINE HYDROCHLORIDE)

Snippet

Sponsor: Janssen Pharmaceutical K.K. | Conditions: Depression | Phase 2 | Status: COMPLETED | Results posted: 2020-10-19